Baird lowered the firm’s price target on Medpace (MEDP) to $358 from $362 and keeps a Neutral rating on the shares. The firm adjusted its model following Q4 results.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MEDP: